Description

Editas Medicine, Inc. is a clinical-stage company dedicated to developing innovative genomic medicines that address a range of serious diseases. The company utilizes its proprietary gene editing platform, which is founded on CRISPR technology. Its robust pipeline includes EDIT-101, currently undergoing Phase 1/2 clinical trials for Leber Congenital Amaurosis 10, a genetic condition causing childhood blindness. Additionally, Editas is developing EDIT-102 for Usher Syndrome 2A, a form of retinitis pigmentosa also linked to hearing loss, and for autosomal dominant retinitis pigmentosa. Another key therapeutic candidate is EDIT-301, aimed at treating sickle cell disease and transfusion-dependent beta-thalassemia. Beyond these programs, the company is advancing gene-edited Natural Killer cell medicines for solid tumors, as well as alpha-beta and gamma delta T cell therapies for various cancers. An early-stage discovery program is also underway for a neurological disease. Editas Medicine maintains strategic collaborations, including a research partnership with Juno Therapeutics, Inc. for engineered T cells in cancer; a strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover and commercialize gene editing therapies for ocular disorders; and research collaborations with Asklepios BioPharmaceutical, Inc. (AskBio) for a neurological disease treatment. Incorporated in 2013, and formerly known as Gengine, Inc. until its name change in November of that year, Editas Medicine, Inc. is based in Cambridge, Massachusetts.